Multiple long-term follow-up studies confirm BRUKINSA’s superior efficacy and favorable tolerability versus ibrutinib in relapsed or refractory CLL Additional ASH data from investigational BTK degrader, BGB-16673, highlight potential first- and… Read More
BIOTECanada welcomes the launch of CanReview, a pan-Canadian initiative supported by the Accelerating Clinical Trials (ACT) Consortium, as a major step forward for Canada’s life sciences ecosystem. By replacing multiple… Read More
KIRKLAND, QC – Merck known as MSD outside the United States and Canada, announced that the province of Saskatchewan has added CAPVAXIVE®, a 21-valent pneumococcal conjugate vaccine, to its publicly… Read More
First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinib among Asian patients. Median overall survival not yet reached and is projected to… Read More
The hospital campus will expand critical services and drive economic growth across the Mid-South. In Memphis, Regional One Health has announced plans for a new hospital campus in the city’s historic Edge District,… Read More
